Table 3.

Prescribing patterns for ms disease-modifying therapies during the Covid-19 Pandemic, n = 42 MS specialists.

How has COVID-19 changed your… prescribing patterns for…	I am MORE likely to recommend starting this DMT during the COVID-19 pandemic.	I am LESS likely to recommend starting this DMT during the COVID-19 pandemic.	I am recommend-ing that at least some of my patients currently on this DMT consider suspending treatment until the pandemic stabilizes.	I am recommend-ing that at least some of my patients currently on this DMT continue treatment at a less frequent dosing interval until the pandemic stabilizes.	I am recommend-ing that at least some of my patients on this DMT obtain laboratory studies MORE frequently during the COVID-19 crisis.	I am recommend-ing that at least some of my patients on this DMT obtain laboratory studies LESS frequently during the COVID-19 crisis.	COVID-19 has not changed how I recommendor prescribe this DMT.
Glatiramer acetate (Copaxone®, Glatopa)	9 (21.4%)	2 (4.8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	30 (71.4%)
Injectable interferons (Avonex®, Betaseron®, Extavia®, Plegridy®, Rebif®)	12 (28.6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	27 (64.3%)
Natalizumab (Tysabri®)	10 (23.8%)	1 (2.4%)	0 (0%)	16 (38.1%)	0 (0%)	0 (0%)	17 (40.5%)
Dimethyl fumarate (Tecfidera®) and diroximel fumarate (Vumerity®)	2 (4.8%)	5 (11.9%)	0 (0%)	0 (0%)	5 (11.9%)	1 (2.4%)	27 (64.3%)
Fingolimod (Gilenya®) and siponimod (Mayzent®)	0 (0%)	17 (40.5%)	0 (0%)	5 (11.9%)	3 (7.1%)	1 (2.4%)	17 (40.5%)
Teriflunomide (Aubagio®)	8 (19.0%)	0 (0%)	0 (0%)	1 (2.4%)	0 (0%)	1 (2.4%)	30 (71.4%)
Cladribine (Mavenclad®)	2 (4.8%)	23 (54.8%)	5 (11.9%)	0 (0%)	2 (4.8%)	0 (0%)	7 (16.7%)
Alemtuzumab (Lemtrada®)	0 (0%)	27 (64.3%)	9 (21.4%)	0 (0%)	0 (0%)	0 (0%)	6 (14.3%)
Ocrelizumab (Ocrevus®) and rituximab (Rituxan®)	0 (0%)	21 (50%)	7 (16.7%)	0 (0%)	5 (11.9%)	0 (0%)	11 (26.2%)